# Orasure Technologies Inc. (OSUR)

**Exchange:** NASDAQ  
**Sector:** Healthcare  
**Market cap:** $308M  
**Price:** $4.19 (+3.97%)

> Orasure Technologies Inc. is a biotechnology company primarily focused on developing point-of-care diagnostic testing and specimen collection devices. Known for its innovation in oral fluid diagnostics, Orasure provides critical solutions in the healthcare sector. Their product portfolio includes diagnostic tests for infectious diseases, such as HIV and Hepatitis C, leveraging easy-to-use, rapid results that are essential for timely medical interventions. Additionally, Orasure offers services and tools for the life sciences, including molecular sample collection and stabilization products utilized in genetic and microbiome research.

The company's products serve a diverse range of sectors, including hospitals, clinics, and public health organizations, contributing significantly to both disease prevention and management. Headquartered in Bethlehem, Pennsylvania, Orasure Technologies plays a pivotal role in advancing public health infrastructure by offering reliable, user-friendly diagnostic tools that empower healthcare providers and patients alike. In the broader market context, Orasure addresses the growing demand for at-home and rapid testing solutions, which have become increasingly crucial components of modern healthcare systems worldwide.

## Income Statement (Annual, USD)

| Fiscal Year | Revenue | Gross Profit | Operating Income | Net Income | EPS (dil.) |
| --- | --- | --- | --- | --- | --- |
| 2025 | $115M | $48M | -$72M | -$69M | — |
| 2024 | $186M | $79M | -$28M | -$20M | — |
| 2023 | $405M | $172M | $33M | $54M | — |
| 2022 | $387M | $148M | -$22M | -$17M | — |
| 2021 | $234M | $118M | -$10M | -$23M | — |
| 2020 | $172M | $102M | -$5M | -$15M | — |
| 2019 | $155M | $95M | $19M | $17M | — |
| 2018 | $182M | $114M | $28M | $20M | — |
| 2017 | $167M | $99M | $40M | $31M | — |
| 2016 | $128M | $88M | $20M | $20M | — |
| 2015 | $120M | $80M | $8M | $8M | — |
| 2014 | $106M | $67M | -$5M | -$5M | — |
| 2013 | $99M | $59M | -$12M | -$11M | — |
| 2012 | $88M | $56M | -$16M | -$15M | — |
| 2011 | $82M | $52M | -$9M | -$9M | — |

## Balance Sheet (Annual, USD)

| Fiscal Year | Total Assets | Total Liabilities | Equity | Cash | Long-term Debt |
| --- | --- | --- | --- | --- | --- |
| 2025 | $403M | $62M | $341M | $199M | — |
| 2024 | $480M | $69M | $410M | $268M | — |
| 2023 | $483M | $52M | $431M | $290M | — |
| 2022 | $444M | $80M | $364M | $84M | — |
| 2021 | $461M | $80M | $381M | $117M | — |
| 2020 | $454M | $56M | $399M | $161M | — |
| 2019 | $349M | $42M | $307M | $76M | — |
| 2018 | $316M | $32M | $283M | $88M | — |
| 2017 | $296M | $38M | $258M | $71M | — |
| 2016 | $208M | $22M | $186M | $108M | — |
| 2015 | $189M | $30M | $159M | $94M | — |
| 2014 | $190M | $31M | $159M | $93M | — |
| 2013 | $184M | $23M | $161M | $93M | — |
| 2012 | $191M | $21M | $170M | $88M | — |
| 2011 | $128M | $28M | $100M | $24M | — |

## Cash Flow (Annual, USD)

| Fiscal Year | Operating Cash Flow | CapEx | Free Cash Flow |
| --- | --- | --- | --- |
| 2025 | -$49M | $4M | -$53M |
| 2024 | $27M | $4M | $24M |
| 2023 | $142M | $6M | $136M |
| 2022 | -$47M | $7M | -$54M |
| 2021 | -$35M | $22M | -$57M |
| 2020 | $6M | $27M | -$21M |
| 2019 | $10M | $9M | $490,000 |
| 2018 | $39M | $6M | $33M |
| 2017 | $28M | $4M | $24M |
| 2016 | $25M | $4M | $20M |
| 2013 | $8M | $2M | $6M |
| 2012 | -$5M | $2M | -$7M |
| 2011 | -$3M | $3M | -$5M |
| 2010 | $4M | $2M | $2M |
| 2009 | -$292,765 | $1M | -$1M |

Source: [CompaniesByCap](https://companiesbycap.com/company/OSUR)